An interesting report in the Website Simply Wall Street today that says that ResMed has secured a significant victory in its patent fight against New York University after the United States Patent Trial and Appeals Board (PTAB) invalidated the claims New York University (NYU) asserted against ResMed. In June 2021, NYU filed a complaint for patent infringement against ResMed in the United States District Court, District of Delaware. NYU’s complaint alleged that the AutoSetTM and AutoRampTM features of ResMed’s AirSenseTM 10 AutoSet flow generators, infringed one or more claims of seven NYU patents.ResMed filed petitions with the PTAB asserting that all the claims asserted against ResMed were invalid. In rulings issued from December 4 to December 7, 2023, the PTAB judges, agreeing with ResMed’s arguments, found that all the challenged claims across the seven patents were invalid. This may help remove some of the negative sentiment around RMD in the US.
RMD Price at posting:
$25.06 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)